Nirvana Life Sciences Inc.
NIRVF
$0.08
$0.080.00%
OTC PK
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 238.30K | 241.20K | 236.60K | 288.80K | 347.00K |
| Depreciation & Amortization | -8.60K | -8.60K | 4.50K | 13.50K | 13.50K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 229.70K | 232.60K | 261.10K | 337.30K | 410.70K |
| Operating Income | -229.70K | -232.60K | -261.10K | -337.30K | -410.70K |
| Income Before Tax | -246.20K | -260.50K | -397.90K | -517.10K | -596.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.25 | -0.26 | -0.40 | -0.52 | -0.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -100.00 | -200.00 | 500.00 | 1.60K | 1.70K |
| Net Income | -246.30K | -260.70K | -397.40K | -515.40K | -594.60K |
| EBIT | -229.70K | -232.60K | -261.10K | -337.30K | -410.70K |
| EBITDA | -186.50K | -219.50K | -246.80K | -323.20K | -383.00K |
| EPS Basic | -0.05 | -0.05 | -0.09 | -0.11 | -0.13 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.04 | -0.05 | -0.06 |
| EPS Diluted | -0.05 | -0.05 | -0.09 | -0.11 | -0.13 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.04 | -0.05 | -0.06 |
| Average Basic Shares Outstanding | 37.29M | 19.29M | 18.68M | 18.68M | 18.68M |
| Average Diluted Shares Outstanding | 37.29M | 19.29M | 18.68M | 18.68M | 18.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |